| Diversicare Of Winfield | |
| 144 County Hwy 14, Winfield, Alabama 35594 | |
| (205) 487-4211 | |
| Name | Diversicare Of Winfield |
|---|---|
| Location | 144 County Hwy 14, Winfield, Alabama |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 123 |
| Occupancy Rate | 76.42% |
| Medicare ID (CCN) | 015376 |
| Legal Business Name | Diversicare Of Winfield Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1841745932 |
| Organization Name | DIVERSICARE OF WINFIELD, LLC |
| Doing Business As | DIVERSICARE OF WINFIELD |
| Address | 144 County Highway 14, Winfield, AL 35594 |
| Phone Number | 205-487-4211 |
News Archive
Living in a disadvantaged urban neighborhood can increase a male residents' risk of contracting HIV, according to researchers at the Johns Hopkins Bloomberg School of Public Health. Their study related disadvantaged neighborhoods to stress and stress to increased injection drug use in male study participants.
APP Pharmaceuticals, Inc., announced today that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer.
Obese men may not process carbohydrates as efficiently as obese women, a condition that can, ultimately, lead to a decrease in fitness level and the development of metabolic disorders.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Living in a disadvantaged urban neighborhood can increase a male residents' risk of contracting HIV, according to researchers at the Johns Hopkins Bloomberg School of Public Health. Their study related disadvantaged neighborhoods to stress and stress to increased injection drug use in male study participants.
APP Pharmaceuticals, Inc., announced today that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer.
Obese men may not process carbohydrates as efficiently as obese women, a condition that can, ultimately, lead to a decrease in fitness level and the development of metabolic disorders.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 3.87 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 19.31 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 26.67 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.43 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.22 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.59 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 1.1 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.04 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 53.02 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.71 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 35.95 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.19 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 7.93 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 31.69 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 11.54 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 91.65 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 88.39 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 66.04 | 82.93 |
News Archive
Living in a disadvantaged urban neighborhood can increase a male residents' risk of contracting HIV, according to researchers at the Johns Hopkins Bloomberg School of Public Health. Their study related disadvantaged neighborhoods to stress and stress to increased injection drug use in male study participants.
APP Pharmaceuticals, Inc., announced today that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer.
Obese men may not process carbohydrates as efficiently as obese women, a condition that can, ultimately, lead to a decrease in fitness level and the development of metabolic disorders.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
› Verified 5 days ago